V. Craig Jordan has been appointed to the Susan G. Komen for the Cure® Scientific Advisory Council. Jordan is the scientific director and vice chairman of the department of oncology at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center.
According to Komen, appointment to the council is reserved for those who have a distinguished record of leadership and commitment to breast cancer research, as well as innovative contributions to breast cancer advancements. Those who are appointed as council members “will serve as distinguished scholars advising and providing expertise to Susan G. Komen for the Cure in peer review, scientific research, sponsored programs, program development and review and public policy.”
Council members serve for renewable, two-year terms during which they are expected to commit approximately 100 to 120 hours each year to council activities. Jordan also will be awarded a $250,000 Komen research grant annually for the duration of his term on the council. The grant must be used to study critical questions in breast cancer.
Jordan is an internationally recognized breast cancer scientist whose research focuses on the response of breast cancer cells to preventive and treatment agents. A pharmacologist, Jordan is recognized by many as the “father” of the anticancer drug tamoxifen.
John A. Katzenellenbogen, Swanlund chairman and professor of chemistry at the University of Illinois, recently was selected to receive the inaugural Philip S. Portoghese Medicinal Chemistry Lectureship. The award, named in honor of Phil Portoghese, the long-standing editor-in-chief of the Journal of Medicinal Chemistry, is administered jointly by the editor-in-chief of the journal and the American Chemical Society Division of Medicinal Chemistry.
The lectureship honors the contributions of an individual who has had a major impact on medicinal chemistry research.
Katzenellenbogen’s research spans chemistry, biology and medicine and involves analysis of steroid receptor structure and function and use of receptors and their ligands in various biological and biomedical applications. He prepared the first-affinity labels and subtype-specific agents for estrogen receptors, and he has probed the receptor with ligands of diverse structure and chemotype, finding compounds with unusually selective biological activities. He also has developed an extensive series of steroid receptor-based agents for imaging receptor-positive breast and prostate tumors by positron emission tomography and obtained the first PET images of these tumors based on their receptor content.